BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Corlanor (Ivabradine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Corlanor (Ivabradine)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07717710-586@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Corlanor (Ivabradine): Phase 1 readout est. (NCT07717710)
DESCRIPTION:Corlanor (Ivabradine)\, phase 1.\nStudy: Ivabradine for Heart R
 ate Reduction During Exercise in Healthy Adults\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 vabradine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07717710
URL:https://assetmemo.bio/drug/ivabradine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05882708-586@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Corlanor (Ivabradine): Phase 4 readout est. (NCT05882708)
DESCRIPTION:Corlanor (Ivabradine)\, phase 4.\nStudy: Effect of Heart Rate C
 ontrol With Ivabradine on Hemodynamic in Patients With Sepsis\nEstimated p
 rimary completion: 31 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ivabradine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05882708
URL:https://assetmemo.bio/drug/ivabradine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797946-586@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Corlanor (Ivabradine): Phase na readout est. (NCT07797946)
DESCRIPTION:Corlanor (Ivabradine)\, phase na.\nStudy: Preoperative Ivabradi
 ne Doses for Hemodynamic Stability in FESS\nEstimated primary completion: 
 1 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivab
 radine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07797946
URL:https://assetmemo.bio/drug/ivabradine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714746-586@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Corlanor (Ivabradine): Phase 3 readout est. (NCT07714746)
DESCRIPTION:Corlanor (Ivabradine)\, phase 3.\nStudy: Ivabradine in the Acut
 e Management of Cardiogenic Shock\nEstimated primary completion: 31 May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ivabradine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07714746
URL:https://assetmemo.bio/drug/ivabradine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07135258-586@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Corlanor (Ivabradine): Phase 4 readout est. (NCT07135258)
DESCRIPTION:Corlanor (Ivabradine)\, phase 4.\nStudy: Atrial Fibrillation: I
 n Search for the Optimal Target for Rate Control\nEstimated primary comple
 tion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ivabradine#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07135258
URL:https://assetmemo.bio/drug/ivabradine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881302-586@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Corlanor (Ivabradine): Phase 2 readout est. (NCT07881302)
DESCRIPTION:Corlanor (Ivabradine)\, phase 2.\nStudy: Effect of Ivabradine o
 n Adolescent Dysautonomia\nEstimated primary completion: May 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ivabradine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07881302
URL:https://assetmemo.bio/drug/ivabradine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07268170-586@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Corlanor (Ivabradine): Phase 2/3 readout est. (NCT07268170)
DESCRIPTION:Corlanor (Ivabradine)\, phase 2/3.\nStudy: Heart Rate Control B
 efore Cardiac Computed Tomography in Adults for the Evaluation of Coronary
  Artery Disease\nEstimated primary completion: 1 September 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ivabradine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07268170
URL:https://assetmemo.bio/drug/ivabradine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
